Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Adjuvant De-Escalated Radiation + Concurrent and Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

NCT03715946 is registered in ClinicalTrials.gov with Robert L. Ferris, MD, PhD as lead sponsor.

NCT NCT03715946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03715946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Adjuvant De-Escalated Radiation + Concurrent and Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
Lead sponsor
Robert L. Ferris, MD, PhD
Phase
Phase 2
Overall status
Completed
Start date
November 16, 2018
Completion date
March 31, 2024
Enrollment
40 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell of head and neck, oropharynx squamous cell carcinoma